Home » Stocks » EQ

Equillium, Inc. (EQ)

Stock Price: $5.50 USD 0.09 (1.66%)
Updated Jul 26, 2021 4:00 PM EDT - Market closed
After-hours: $5.51 +0.01 (0.18%) Jul 26, 4:33 PM
Market Cap 157.11M
Revenue (ttm) n/a
Net Income (ttm) -30.97M
Shares Out 27.33M
EPS (ttm) -1.36
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 26
Last Price $5.50
Previous Close $5.41
Change ($) 0.09
Change (%) 1.66%
Day's Open 5.41
Day's Range 5.34 - 5.55
Day's Volume 42,348
52-Week Range 3.47 - 13.19

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Equillium Inc (NASDAQ: EQ) completed an End-of-Phase 1 meeting with the FDA, confirming to advance itolizumab into a single Phase 3 pivotal study in first-line treatment of acute graft-versus-host disea...

1 week ago - Benzinga

Single pivotal Phase 3 study in acute graft-versus-host disease to support filing of biologics license application

2 weeks ago - GlobeNewsWire

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

Other stocks mentioned: CKPT, FLXN, RSLS
1 month ago - 24/7 Wall Street

Equillium Inc (NASDAQ: EQ) has announced positive topline data from the Phase 1b EQUATE study evaluating itolizumab in first-line acute graft-versus-host-disease (aGVHD). The results were presented at t...

1 month ago - Benzinga

Itolizumab continues to demonstrate favorable safety and efficacy profile

1 month ago - GlobeNewsWire

Whole blood and proteomic stabilized blood assay used to elicit clinical pharmacodynamic CD6 biomarker in autoimmune diseases Whole blood and proteomic stabilized blood assay used to elicit clinical pha...

1 month ago - GlobeNewsWire

LA JOLLA, Calif., June 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, anno...

1 month ago - GlobeNewsWire

LA JOLLA, Calif., June 07, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today...

1 month ago - GlobeNewsWire

Presentation and conference call will include topline data from all cohorts

1 month ago - GlobeNewsWire

Announced favorable data from Phase 1b EQUALISE study in patients with systemic lupus erythematosus

2 months ago - GlobeNewsWire

LA JOLLA, Calif., May 13, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today...

2 months ago - GlobeNewsWire

Presentations highlight the pathogenic role of the CD6-ALCAM pathway, the immunologic impact of modulating this pathway with itolizumab, and pharmacodynamic assays to monitor this in patients Presentati...

2 months ago - GlobeNewsWire

Equillium Inc (NASDAQ: EQ) has reported topline data from the Type A group of the Phase 1b EQUALISE study evaluating itolizumab in patients with systemic lupus erythematosus (SLE). Data from the study s...

3 months ago - Benzinga

Itolizumab administered subcutaneously was safe and well tolerated in patients with systemic lupus erythematosus

3 months ago - GlobeNewsWire

EQUATE acute graft-versus host disease (aGVHD) study observed  rapid response and durability through day 85

4 months ago - GlobeNewsWire

Higher dose cohorts demonstrated 100% overall response rate, resulting in substantial  reduction in baseline corticosteroid use

5 months ago - GlobeNewsWire

LA JOLLA, Calif., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today...

5 months ago - GlobeNewsWire

LA JOLLA, Calif., Feb. 05, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today...

5 months ago - GlobeNewsWire

LA JOLLA, Calif., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today...

5 months ago - GlobeNewsWire

LA JOLLA, Calif., Jan. 22, 2021 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ) a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, today...

6 months ago - GlobeNewsWire

Studies further support itolizumab's potential as treatment for aGVHD patients Studies further support itolizumab's potential as treatment for aGVHD patients

7 months ago - GlobeNewsWire

Equillium (EQ) decides to not initiate a phase III study on its candidate, itolizumab, for the treatment of hospitalized COVID-19 patients at this time.

8 months ago - Zacks Investment Research

Shares of Equillium Inc. tumbled 12.6% in premarket trading Wednesday, after the biotechnology company said it decided not to initiate a Phase 3 trial its itolizumab for the treatment of hospitalized CO...

8 months ago - Market Watch

Analyst Day scheduled for December 4, 2020 Analyst Day scheduled for December 4, 2020

8 months ago - GlobeNewsWire

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, toda...

8 months ago - GlobeNewsWire

LA JOLLA, Calif., Nov. 10, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, toda...

8 months ago - GlobeNewsWire

100% overall response rate in dose cohort 3 and 80% overall response rate across all cohorts to date

8 months ago - GlobeNewsWire

Studies  further validate  ongoing clinical  development of itolizumab for the treatment  of  systemic  lupus   erythematosus and lupus  nephritis

8 months ago - GlobeNewsWire

Equillium (EQ) stock is seeing gains on Friday after getting the go-ahead from the FDA for a drug trial treating the coronavirus. The post EQ Stock: 6 Things to Know about Biotech Company Equillium appe...

8 months ago - InvestorPlace

Equillium Inc. (NASDAQ: EQ) shares jumped on Friday after the company announced a key update from the U.S.

8 months ago - 24/7 Wall Street

Equillium p lans to initiate global Phase 3 COVID-19 trial – EQUINOX – during Q4  2020

8 months ago - GlobeNewsWire

Is (EQ) Outperforming Other Medical Stocks This Year?

9 months ago - Zacks Investment Research

LA JOLLA, Calif., Sept. 17, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, t...

10 months ago - GlobeNewsWire

Equillium anticipates filing a U.S. IND for Itolizumab for COVID-19 and initiating a global Phase 3 clinical study in Q4 2020

10 months ago - GlobeNewsWire

LA JOLLA, Calif., Sept. 03, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to ...

10 months ago - GlobeNewsWire

LA JOLLA, Calif., Aug. 18, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to...

11 months ago - GlobeNewsWire

LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to...

11 months ago - GlobeNewsWire

LA JOLLA, Calif., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to...

11 months ago - GlobeNewsWire

LA JOLLA, Calif., Aug. 12, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company developing itolizumab to treat severe autoimmune and inflammatory disorders, to...

11 months ago - GlobeNewsWire

Complete response observed in five of seven patients in first two dose cohorts

11 months ago - GlobeNewsWire

LA JOLLA, Calif., July 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop novel products to t...

11 months ago - GlobeNewsWire

Equillium (EQ) news for Tuesday concerning a deal with Jefferies (JEF) to sell shares of EQ stock has it falling on Tuesday. The post Equillium News: Why EQ Stock Is Plummeting 46% Today appeared first ...

1 year ago - InvestorPlace

Equillium (EQ) soars on positive results on pipeline candidate, itolizumab, for COVID-19.

1 year ago - Zacks Investment Research

Equillium shares topline results of patients treated with itolizumab in clinical trial conducted in India by partner Biocon

1 year ago - GlobeNewsWire

LA JOLLA, Calif., May 13, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat seve...

1 year ago - GlobeNewsWire

LA JOLLA, Calif., March 30, 2020 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging deep understanding of immunobiology to develop products to treat se...

1 year ago - GlobeNewsWire

EQUIP and EQUALISE Studies to be Paused in Response to the COVID-19 Pandemic

1 year ago - GlobeNewsWire

Maple Fung, M.D., joins as vice president clinical development Matthew Ritter, Ph.D., joins as vice president corporate development

1 year ago - GlobeNewsWire

About EQ

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. Its primary product candidate is itolizumab, a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase 1b/2 clinical trials for the treatment of acute graft-versus-host disease; and Phase 1 clinical trial for the treatment of asthma and lupus nephritis. The company was formerly known as Attenuate Biopharmaceu... [Read more...]

Industry
Biotechnology
IPO Date
Oct 11, 2018
CEO
Bruce Steel
Employees
31
Stock Exchange
NASDAQ
Ticker Symbol
EQ
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for Equillium stock is "Strong Buy." The 12-month stock price forecast is 13.60, which is an increase of 147.27% from the latest price.

Price Target
$13.60
(147.27% upside)
Analyst Consensus: Strong Buy